Table 4. The comparison between adverse events reported by female alopecia patients exposed to finasteride and minoxidil.
| Adverse Effect | Drug | Affected Cases | Total Cases | Proportion1 | PRR (95% CI)2 | P-value3 |
|---|---|---|---|---|---|---|
| Abortion Induced | Finasteride | 11 | 60 | 18.33% | 9.07 (2.08 - 39.53) | 1.93×10−3** |
| Minoxidil | 2 | 99 | 2.02% | |||
| Abortion Spontaneous | Finasteride | 8 | 60 | 13.33% | 6.60 (1.45 - 30.06) | 0.016* |
| Minoxidil | 2 | 99 | 2.02% | |||
| Arthralgia | Finasteride | 3 | 60 | 5.00% | 0.55 (0.15 - 1.95) | 0.54 |
| Minoxidil | 9 | 99 | 9.09% | |||
| Arthritis | Finasteride | 3 | 60 | 5.00% | N/A | 0.057 |
| Minoxidil | 0 | 99 | 0.00% | |||
| Dermatitis Contact | Finasteride | 2 | 60 | 3.33% | 0.37 (0.08 - 1.66) | 0.33 |
| Minoxidil | 9 | 99 | 9.09% | |||
| Dizziness | Finasteride | 2 | 60 | 3.33% | 0.41 (0.09 - 1.87) | 0.33 |
| Minoxidil | 8 | 99 | 8.08% | |||
| Endometrial Hypertrophy | Finasteride | 4 | 60 | 6.67% | N/A | 0.022* |
| Minoxidil | 0 | 99 | 0.00% | |||
| Fatigue | Finasteride | 3 | 60 | 5.00% | 0.99 (0.25 - 3.99) | 1.00 |
| Minoxidil | 5 | 99 | 5.05% | |||
| Menorrhagia | Finasteride | 4 | 60 | 6.67% | 6.60 (0.76 - 57.68) | 0.077 |
| Minoxidil | 1 | 99 | 1.01% | |||
| Menstruation Irregular | Finasteride | 4 | 60 | 6.67% | 6.60 (0.76 - 57.68) | 0.077 |
| Minoxidil | 1 | 99 | 1.01% | |||
| Nausea | Finasteride | 2 | 60 | 3.33% | 0.47 (0.10 - 2.19) | 0.49 |
| Minoxidil | 7 | 99 | 7.07% | |||
| Palpitations | Finasteride | 0 | 60 | 0.00% | 0.00 | 0.52 |
| Minoxidil | 8 | 99 | 8.08% | |||
| Paternal Drugs Affecting Fetus | Finasteride | 5 | 60 | 8.33% | N/A | 8.89×10−3** |
| Minoxidil | 0 | 99 | 0.00% | |||
| Phalangeal Agenesis | Finasteride | 3 | 60 | 5.00% | N/A | 0.057 |
| Minoxidil | 0 | 99 | 0.00% | |||
| Pruritus | Finasteride | 1 | 60 | 1.67% | 0.33 (0.04 - 2.76) | 0.41 |
| Minoxidil | 5 | 99 | 5.05% | |||
| Swelling Face | Finasteride | 0 | 60 | 0.00% | 0.00 | 0.027* |
| Minoxidil | 9 | 99 | 9.09% | |||
| Tachycardia | Finasteride | 0 | 60 | 0.00% | 0.00 | 0.087 |
| Minoxidil | 6 | 99 | 6.06% | |||
| Uterine Cervix Stenosis | Finasteride | 4 | 60 | 6.67% | N/A | 0.022* |
| Minoxidil | 0 | 99 | 0.00% | |||
| Visual Acuity Reduced | Finasteride | 0 | 60 | 0.00% | 0.00 | 0.16 |
| Minoxidil | 5 | 99 | 5.05% | |||
| Weight Increased | Finasteride | 0 | 60 | 0.00% | 0.00 | 0.16 |
| Minoxidil | 5 | 99 | 5.05% |
1
The proportion value is computed as the number of affected cases divided by the number of total cases.
2
A PRR significantly greater (or lower) than 1.0 means the risk is higher for finasteride (or minoxidil).
3
*, p < 0.05; **, p < 0.01